PURE EP™ Study Shows Promising Results at Asia-Pacific Heart Rhythm Society Conference

Westport, CT, Dec. 14, 2022

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, recently presented exciting findings at the premier Asia-Pacific Heart Rhythm Society Conference.

Update: BioSig’s PURE EP™ System Demonstrates Potential for Cardiac Care Advancements

During the conference, BioSig showcased the results of studies conducted using their innovative PURE EP™ System. The findings demonstrated a significant improvement in accuracy and precision in intracardiac signal visualization, which could revolutionize the way cardiac arrhythmias are diagnosed and treated.

This breakthrough technology has the potential to enhance patient outcomes and streamline the process of diagnosing and treating cardiac conditions. By providing healthcare professionals with clearer and more detailed signals, the PURE EP™ System enables more accurate decision-making and precise treatment delivery.

With these promising results, BioSig is paving the way for a new standard of care in cardiac electrophysiology. The Company’s commitment to advancing medical technology and improving patient care is evident in the success of the PURE EP™ System.

How Will This Impact Me?

For patients suffering from cardiac arrhythmias or other heart conditions, the advancements made by BioSig’s PURE EP™ System offer hope for more accurate diagnoses and personalized treatment plans. With improved signal visualization, healthcare providers can make more informed decisions about patient care, leading to better outcomes and potentially shorter recovery times.

How Will This Impact the World?

The introduction of the PURE EP™ System represents a significant step forward in the field of cardiac electrophysiology. By advancing signal processing technology and enhancing visualization capabilities, BioSig is shaping the future of healthcare and setting a new standard for cardiac care worldwide. The potential impact of this technology extends beyond individual patient outcomes, with the potential to improve the efficiency and effectiveness of cardiac procedures on a global scale.

Conclusion

The recent findings presented by BioSig Technologies at the Asia-Pacific Heart Rhythm Society Conference highlight the groundbreaking advancements made possible by the PURE EP™ System. With its unprecedented accuracy and precision, this technology has the potential to transform the way cardiac arrhythmias are diagnosed and treated, ultimately improving patient outcomes and advancing the field of cardiac electrophysiology.